Both preclinical and clinical studies demonstrate that the IGF-1R is overexpressed and hyperphosphorylated across multiple breast cancer subtypes, thereby providing a mechanistic basis for its oncogenic contribution [54]. The gene discussed is IGF1R; the disease is breast carcinoma.